189 related articles for article (PubMed ID: 20429590)
1. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.
Jones DR; Kim SY; Guderyon M; Yun CH; Moran JH; Miller GP
Chem Res Toxicol; 2010 May; 23(5):939-45. PubMed ID: 20429590
[TBL] [Abstract][Full Text] [Related]
2. Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases.
Zielinska A; Lichti CF; Bratton S; Mitchell NC; Gallus-Zawada A; Le VH; Finel M; Miller GP; Radominska-Pandya A; Moran JH
J Pharmacol Exp Ther; 2008 Jan; 324(1):139-48. PubMed ID: 17921187
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins.
Kim SY; Kang JY; Hartman JH; Park SH; Jones DR; Yun CH; Boysen G; Miller GP
Drug Metab Lett; 2012 Sep; 6(3):157-64. PubMed ID: 23331088
[TBL] [Abstract][Full Text] [Related]
4. Regioselectivity significantly impacts microsomal glucuronidation efficiency of R/S-6, 7-, and 8-hydroxywarfarin.
Kim SY; Jones DR; Kang JY; Yun CH; Miller GP
Xenobiotica; 2019 Apr; 49(4):397-403. PubMed ID: 29543105
[TBL] [Abstract][Full Text] [Related]
5. Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7-hydroxylation.
Zhang ZY; Kerr J; Wexler RS; Li HY; Robinson AJ; Harlow PP; Kaminsky LS
Thromb Res; 1997 Nov; 88(4):389-98. PubMed ID: 9526963
[TBL] [Abstract][Full Text] [Related]
6. Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases.
Bratton SM; Mosher CM; Khallouki F; Finel M; Court MH; Moran JH; Radominska-Pandya A
J Pharmacol Exp Ther; 2012 Jan; 340(1):46-55. PubMed ID: 21972237
[TBL] [Abstract][Full Text] [Related]
7. Effect of glimepiride and glibenclamide on S-warfarin 7-hydroxylation by human liver microsomes, recombinant human CYP2C9.1 and CYP2C9.3.
Iwakawa S; Miyashita K; Hashimoto Y; Kuroda T
Biol Pharm Bull; 2006 Sep; 29(9):1983-5. PubMed ID: 16946524
[TBL] [Abstract][Full Text] [Related]
8. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.
Wienkers LC; Wurden CJ; Storch E; Kunze KL; Rettie AE; Trager WF
Drug Metab Dispos; 1996 May; 24(5):610-4. PubMed ID: 8723744
[TBL] [Abstract][Full Text] [Related]
9. Effect of ethanol on S-warfarin and diclofenac metabolism by recombinant human CYP2C9.1.
Tatsumi A; Ikegami Y; Morii R; Sugiyama M; Kadobayashi M; Iwakawa S
Biol Pharm Bull; 2009 Mar; 32(3):517-9. PubMed ID: 19252308
[TBL] [Abstract][Full Text] [Related]
10. CYP2C9-catalyzed metabolism of S-warfarin to 7-hydroxywarfarin in vivo and in vitro in chimeric mice with humanized liver.
Inoue T; Nitta K; Sugihara K; Horie T; Kitamura S; Ohta S
Drug Metab Dispos; 2008 Dec; 36(12):2429-33. PubMed ID: 18784266
[TBL] [Abstract][Full Text] [Related]
11. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.
Rettie AE; Korzekwa KR; Kunze KL; Lawrence RF; Eddy AC; Aoyama T; Gelboin HV; Gonzalez FJ; Trager WF
Chem Res Toxicol; 1992; 5(1):54-9. PubMed ID: 1581537
[TBL] [Abstract][Full Text] [Related]
12. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations.
Brantley SJ; Oberlies NH; Kroll DJ; Paine MF
J Pharmacol Exp Ther; 2010 Mar; 332(3):1081-7. PubMed ID: 19934397
[TBL] [Abstract][Full Text] [Related]
13. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of warfarin elimination and its clinical implications.
Takahashi H; Echizen H
Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
[TBL] [Abstract][Full Text] [Related]
15. Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy.
Zhang N; Seguin RP; Kunze KL; Zhang YY; Jeong H
Drug Metab Dispos; 2013 Dec; 41(12):2114-23. PubMed ID: 24046330
[TBL] [Abstract][Full Text] [Related]
16. R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.
Yong WP; Kim TW; Undevia SD; Innocenti F; Ratain MJ
Eur J Cancer; 2009 Jul; 45(11):1904-8. PubMed ID: 19464879
[TBL] [Abstract][Full Text] [Related]
17. Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites.
Pugh CP; Pouncey DL; Hartman JH; Nshimiyimana R; Desrochers LP; Goodwin TE; Boysen G; Miller GP
Arch Biochem Biophys; 2014 Dec; 564():244-53. PubMed ID: 25447818
[TBL] [Abstract][Full Text] [Related]
18. Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin.
Jones DR; Kim SY; Boysen G; Yun CH; Miller GP
Drug Metab Lett; 2010 Dec; 4(4):213-9. PubMed ID: 20615193
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.
Hemeryck A; De Vriendt C; Belpaire FM
Eur J Clin Pharmacol; 1999 Feb; 54(12):947-51. PubMed ID: 10192756
[TBL] [Abstract][Full Text] [Related]
20. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
Yamazaki H; Inoue K; Shimada T
Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
